ArticleCancer cell international2025
The Kv10.1 potassium channel, driver of hypoxia-induced EMT and breast cancer cell aggressiveness.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Antihistamine Astemizole Potentiates the Antitumor Efficacy of Sorafenib in Hepatocellular Carcinoma by Suppressing Proliferation, Metastasis, and Angiogenesis.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKv10.1 potassium channel has been shown to be involved in breast cancer luminal cell proliferation and survival as well as migration in basal cell model in normoxia. Moreover, it is clearly established that solid tumors present a hypoxic center. Currently, few information is available about the involvement of the Kv10.1 channel in hypoxic context in breast cancer progression.
methodsWe explored the role of Kv10.1 in the hypoxia-induced aggressiveness promotion of different breast cancer cell models: luminal A (MCF-7 cells), HER2-overexpressing (SKBr3 cells) and basal subtype (MDA-MB-231 cells) by using complementary approaches of cell biology assay, western blot and qPCR.
resultsOur results show that Kv10.1 expression and function are related to hypoxia and HIF-1α. Under hypoxia, we demonstrated that Kv10.1 is a major actor of the migration and it regulates the hypoxia-induced EMT in the three cells models by promoting the mesenchymal phenotype. Finally, after RNAseq comparison of cells expressing or not the channel in hypoxia condition, we highlighted the involvement of the β1-integrin / FAK, AKT and ERK pathways in the MDA-MB-231 breast cancer cell aggressiveness.
conclusionWe demonstrated, for the first time, the impact of Kv10.1 channel in hypoxia-induced aggressivity of breast cancer cells demonstrating its potential use as a complementary target to fight against metastasis development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.